Brief: Resverlogix Receives US FDA Breakthrough Therapy Designation For Apabetalone
03/02/2020 12:39
Feb 3 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX RECEIVES US FDA BREAKTHROUGH THERAPY
DESIGNATION FOR
APABETALONE
Source text for Eikon: ID:nGNX5QSMP7
Further company coverage: RVX.TO
(Reuters.Briefs@thomsonreuters.com)
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment